This site is intended for healthcare professionals

NMPA (China) approves Verkazia to treat vernal keratoconjunctivitis (VKC) in children and adolescents.- Santen

Read time: 1 mins
Published:15th May 2022

China’s National Medical Products Administration (NMPA) granted the approval to the company’s local subsidiary. Santen plans to launch the drug by the end of March next year. VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, which causes severe inflammation of the ocular surface. It is characterized by symptoms like intense itching, painful eyes, and light sensitivity.

Condition: Vernal Keratoconjunctivitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.